 SOUTH SAN FRANCISCO, Calif., April 15, 2021 PRNewswire -- IDEAYA Biosciences, Inc. NASDAQ: IDYA, a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that the company plans to issue a pre-market press release and conduct a webcast on Friday, April 16, 2021, to discuss clinical data from the ongoing Phase 12 trial evaluating darovasertib IDE196 as monotherapy and darovasertib and binimetinib combination in patients with metastatic uveal melanoma MUM ClinicalTrials.gov Identifier: NCT03947385. 